Alveus Therapeutics
PrivateLast Round
Series A
Extension
Feb 24, 2026
Total Funding Raised
$234M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Alveus Therapeutics is a biotechnology company developing next-generation therapies for obesity and metabolic diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Alveus Therapeutics Comparables
Compare Alveus Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Verdiva Bio | 86% | |
| Antag Therapeutics | 85% | |
| Pep2Tango Therapeutics Inc. | 85% |
Alveus Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Feb 24, 2026 | ||||
| Series A | Jan 8, 2026 |
Alveus Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Avego Management | Series A, Series A Extension |
| Omega Funds | Series A, Series A Extension |
| Andera Partners | Series A, Series A Extension |
| New Rhein Healthcare Investors | Series A, Series A Extension |
| Novo Holdings | Series A Extension |
| Sanofi Ventures | Series A Extension |
| Jeito Capital | Series A Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 12, 2026
Open roles increased to 8, 2.2x the trailing average.
- Sep 28, 2026
Open roles increased to 6, double the trailing average.
Recent news
Latest coverage and updates
- hiresSep 1, 2026
Alveus Therapeutics group announces the appointment of John Stubenrauch, PhD, as Chief Technology Officer, adding him to its executive leadership team as it opens a new office in Massachusetts on Sep 1st '26.
Alveus Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Alveus Therapeutics's valuation, stock price, and market status.
Is Alveus Therapeutics a public or private company?
Alveus Therapeutics is a private company.
What is the current stock price of Alveus Therapeutics?
Alveus Therapeutics is a private company, so its shares have no public market price. Caplight tracks Alveus Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Alveus Therapeutics worth (valuation)?
Valuation information for Alveus Therapeutics is not publicly available.
Can I buy Alveus Therapeutics stock?
Alveus Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Alveus Therapeutics's last funding round?
Alveus Therapeutics's most recent funding round was Series A Extension on February 24, 2026.
Who are the main investors in Alveus Therapeutics?
Key investors in Alveus Therapeutics include Omega Funds, Andera Partners, New Rhein Healthcare Investors.
Will Alveus Therapeutics IPO soon?
No public IPO plans have been announced for Alveus Therapeutics.
How can I track Alveus Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Alveus Therapeutics's shares on secondary markets.